This morning, Peregrine Pharmaceuticals (NASDAQ: PPHM) released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.